Study shows shift in GLP-1 drug use for obesity, not diabetes
WEBJul 23, 2024 · The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 · About 1 million people became new GLP-1 users during that period in time, results show. Researchers classified them based on whether they had diabetes, obesity or some other related medical condition. GLP-1 drugs work by adjusting a person’s hormone levels and suppressing appetite.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 · Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, whites, and those with a BMI of 30 or more, indicating obesity, results show.
Research shows GLP-1 drugs are effective but complex
WEBMay 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic - MedicineNet
WEBJul 23, 2024 · The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat type 2 diabetes, a new study finds. New prescriptions for these drugs have doubled among people who have obesity but not diabetes, investigators found.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 · GLP-1 drugs work by adjusting a person’s hormone levels and suppressing appetite. Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, whites, and those with a BMI of 30 or more, indicating obesity, results show. The findings were published July …
Study indicates surge in GLP-1RA prescriptions to treat obesity …
WEBJul 22, 2024 · Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists...
New Cedars-Sinai Study Investigates Shifting Trends in GLP-1RA …
WEBInvestigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity - Medscape
WEBJul 23, 2024 · Since 2020, prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for obesity without diabetes has risen, whereas their use for the treatment of type 2 diabetes (T2D) has...
Winning researchers unlocked GLP-1 drugs for obesity | Science
WEBMay 30, 2024 · The two researchers started with a list of gut hormones to target for obesity drugs, ultimately picking glucagon. Glucagon works in the opposite direction of insulin—helping to release glucose into the blood when levels are too low, which can happen sometimes for diabetic patients.